Long-chain polyunsaturated fatty acids (LCPUFAs) play specific roles during the perinatal period and are very important nutrients to consider. The possible effects of LCPUFAs, particularly docosahexaenoic acid (DHA), on various clinical outcomes of preterm infants are discussed in this paper. Since DHA accumulates in the central nervous system during development, a lot of attention has focused on the effects of DHA on neurodevelopment. Experimental studies as well as recent clinical trials show that providing larger amounts of DHA than currently and routinely provided is associated with better neurological outcomes at 18 months to 2 years. This early advantage, however, does not seem to translate into detectable change in visual and neurodevelopmental outcomes or behavior when assessed in childhood. There is growing evidence that, in addition to effects on development, omega-3 LCPUFAs may reduce the incidence or severity of neonatal morbidities by affecting different steps of the immune and anti-inflammatory response. Studies in preterm infants suggest that the omega-3 LCPUFAs may play a significant role by reducing the risk of bronchopulmonary dysplasia, necrotizing enterocolitis and possibly retinopathy of prematurity and sepsis. Overall, evidence is increasing to support the benefits of high-dose DHA for various health outcomes of preterm infants. These findings are of major clinical relevance mainly because infants born preterm are at particularly high risk for a nutritional deficit in omega-3 fatty acids, predisposing to adverse neonatal outcomes. Further studies are warranted to address these issues as well as to more precisely determine the LCPUFA requirement in order to favor the best possible outcomes of preterm infants.

Keywords:
Docosahexaenoic acid, Enteral nutrition, Parenteral nutrition, Polyunsaturated fatty acids, Premature infant
1.
Ancel PY, Goffinet F, Kuhn P, et al: Survival and morbidity of preterm children born at 22 through 34 weeks' gestation in France in 2011: results of the EPIPAGE-2 cohort study. JAMA Pediatr 2015;169:230-238.
2.
Georgieff MK: Nutrition and the developing brain: nutrient priorities and measurement. Am J Clin Nutr 2007;85:614S-620S.
3.
Franz AR, Pohlandt F, Bode H, Mihatsch WA, Sander S, Kron M, Steinmacher J: Intrauterine, early neonatal, and postdischarge growth and neurodevelopmental outcome at 5.4 years in extremely preterm infants after intensive neonatal nutritional support. Pediatrics 2009;123:e101-e109.
4.
dit Trolli SE, Kermorvant-Duchemin E, Huon C, Bremond-Gignac D, Lapillonne A: Early lipid supply and neurological development at one year in very low birth weight (VLBW) preterm infants. Early Hum Dev 2012;88(suppl 1):S25-S29.
5.
Ehrenkranz RA, Das A, Wrage LA, Poindexter BB, Higgins RD, Stoll BJ, Oh W: Early nutrition mediates the influence of severity of illness on extremely LBW infants. Pediatr Res 2011;69:522-529.
6.
Agostoni C, Buonocore G, Carnielli VP, et al: Enteral nutrient supply for preterm infants: commentary from the European society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition. J Pediatr Gastroenterol Nutr 2010;50:85-91.
7.
Georgieff MK, Innis SM: Controversial nutrients that potentially affect preterm neurodevelopment: essential fatty acids and iron. Pediatr Res 2005;57:99R-103R.
8.
Lapillonne A, Groh-Wargo S, Gonzalez CH, Uauy R: Lipid needs of preterm infants: updated recommendations. J Pediatr 2013;162: S37-S47.
9.
Innis SM: Essential fatty acid transfer and fetal development. Placenta 2005;26(suppl A): S70-S75.
10.
Haggarty P: Effect of placental function on fatty acid requirements during pregnancy. Eur J Clin Nutr 2004;58:1559-1570.
11.
Lapillonne A, Jensen CL: Reevaluation of the DHA requirement for the premature infant. Prostaglandins Leukot Essent Fatty Acids 2009;81:143-150.
12.
Kuipers RS, Luxwolda MF, Offringa PJ, Boersma ER, Dijck-Brouwer DA, Muskiet FA: Fetal intrauterine whole body linoleic, arachidonic and docosahexaenoic acid contents and accretion rates. Prostaglandins Leukot Essent Fatty Acids 2012;86:13-20.
13.
Lapillonne A, Eleni Dit Trolli S, Kermorvant-Duchemin E: Postnatal docosahexaenoic acid deficiency is an inevitable consequence of current recommendations and practice in preterm infants. Neonatology 2010;98:397-403.
14.
McCann JC, Ames BN: Is docosahexaenoic acid, an n-3 long-chain polyunsaturated fatty acid, required for development of normal brain function? An overview of evidence from cognitive and behavioral tests in humans and animals. Am J Clin Nutr 2005;82:281-295.
15.
Henriksen C, Haugholt K, Lindgren M, Aurvag AK, Ronnestad A, Gronn M, Solberg R, Moen A, Nakstad B, Berge RK, Smith L, Iversen PO, Drevon CA: Improved cognitive development among preterm infants attributable to early supplementation of human milk with docosahexaenoic acid and arachidonic acid. Pediatrics 2008;121:1137-1145.
16.
Isaacs EB, Ross S, Kennedy K, Weaver LT, Lucas A, Fewtrell MS: 10-year cognition in preterms after random assignment to fatty acid supplementation in infancy. Pediatrics 2011;128:e890-e898.
17.
Makrides M, Gibson RA, McPhee AJ, Collins CT, Davis PG, Doyle LW, Simmer K, Colditz PB, Morris S, Smithers LG, Willson K, Ryan P: Neurodevelopmental outcomes of preterm infants fed high-dose docosahexaenoic acid: a randomized controlled trial. JAMA 2009;301:175-182.
18.
Westerberg AC, Schei R, Henriksen C, Smith L, Veierod MB, Drevon CA, Iversen PO: Attention among very low birth weight infants following early supplementation with docosahexaenoic and arachidonic acid. Acta Paediatr 2011;100:47-52.
19.
Molloy C, Doyle LW, Makrides M, Anderson PJ: Docosahexaenoic acid and visual functioning in preterm infants: a review. Neuropsychol Rev 2012;22:425-437.
20.
Lapillonne A: Enteral and parenteral lipid requirements of preterm infants. World Rev Nutr Diet 2014;110:82-98.
21.
Schulzke SM, Patole SK, Simmer K: Long-chain polyunsaturated fatty acid supplementation in preterm infants. Cochrane Database Syst Rev 2011:CD000375.
22.
Fewtrell MS, Abbott RA, Kennedy K, Singhal A, Morley R, Caine E, Jamieson C, Cockburn F, Lucas A: Randomized, double-blind trial of long-chain polyunsaturated fatty acid supplementation with fish oil and borage oil in preterm infants. J Pediatr 2004;144:471-479.
23.
Almaas AN, Tamnes CK, Nakstad B, Henriksen C, Grydeland H, Walhovd KB, Fjell AM, Iversen PO, Drevon CA: Diffusion tensor imaging and behavior in premature infants at 8 years of age, a randomized controlled trial with long-chain polyunsaturated fatty acids. Early Hum Dev 2016;95:41-46.
24.
Almaas AN, Tamnes CK, Nakstad B, Henriksen C, Walhovd KB, Fjell AM, Due-Tonnessen P, Drevon CA, Iversen PO: Long-chain polyunsaturated fatty acids and cognition in VLBW infants at 8 years: an RCT. Pediatrics 2015;135:972-980.
25.
Smithers LG, Gibson RA, McPhee A, Makrides M: Higher dose of docosahexaenoic acid in the neonatal period improves visual acuity of preterm infants: results of a randomized controlled trial. Am J Clin Nutr 2008;88:1049-1056.
26.
Smithers LG, Collins CT, Simmonds LA, Gibson RA, McPhee A, Makrides M: Feeding preterm infants milk with a higher dose of docosahexaenoic acid than that used in current practice does not influence language or behavior in early childhood: a follow-up study of a randomized controlled trial. Am J Clin Nutr 2010;91:628-634.
27.
Collins CT, Gibson RA, Anderson PJ, McPhee AJ, Sullivan TR, Gould JF, Ryan P, Doyle LW, Davis PG, McMichael JE, French NP, Colditz PB, Simmer K, Morris SA, Makrides M: Neurodevelopmental outcomes at 7 years' corrected age in preterm infants who were fed high-dose docosahexaenoic acid to term equivalent: a follow-up of a randomised controlled trial. BMJ Open 2015;5:e007314.
28.
Molloy CS, Stokes S, Makrides M, Collins CT, Anderson PJ, Doyle LW: Long-term effect of high-dose supplementation with DHA on visual function at school age in children born at <33 weeks gestational age: results from a follow-up of a randomized controlled trial. Am J Clin Nutr 2016;103:268-275.
29.
Dammann O, Leviton A: Inflammation, brain damage and visual dysfunction in preterm infants. Semin Fetal Neonatal Med 2006;11:363-368.
30.
Strunk T, Inder T, Wang X, Burgner D, Mallard C, Levy O: Infection-induced inflammation and cerebral injury in preterm infants. Lancet Infect Dis 2014;14:751-762.
31.
Marchant EA, Kan B, Sharma AA, van Zanten A, Kollmann TR, Brant R, Lavoie PM: Attenuated innate immune defenses in very premature neonates during the neonatal period. Pediatr Res 2015;78:492-497.
32.
Paananen R, Husa AK, Vuolteenaho R, Herva R, Kaukola T, Hallman M: Blood cytokines during the perinatal period in very preterm infants: relationship of inflammatory response and bronchopulmonary dysplasia. J Pediatr 2009;154:39-43.e33.
33.
Waitzberg DL, Torrinhas RS: Fish oil lipid emulsions and immune response: what clinicians need to know. Nutr Clin Pract 2009;24:487-499.
34.
Serhan CN, Chiang N, Van Dyke TE: Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008;8:349-361.
35.
Poindexter BB, Feng R, Schmidt B, Aschner JL, Ballard RA, Hamvas A, Reynolds AM, Shaw PA, Jobe AH: Comparisons and limitations of current definitions of bronchopulmonary dysplasia for the prematurity and respiratory outcomes program. Ann Am Thorac Soc 2015;12:1822-1830.
36.
Hasselmann M, Reimund JM: Lipids in the nutritional support of the critically ill patients. Curr Opin Crit Care 2004;10:449-455.
37.
Houeijeh A, Aubry E, Coridon H, Montaigne K, Sfeir R, Deruelle P, Storme L: Effects of n-3 polyunsaturated fatty acids in the fetal pulmonary circulation. Crit Care Med 2011;39:1431-1438.
38.
Rogers LK, Valentine CJ, Pennell M, Velten M, Britt RD, Dingess K, Zhao X, Welty SE, Tipple TE: Maternal DHA supplementation decreases lung inflammation in hyperoxia-exposed newborn mice. J Nutr 2010;141:214-222.
39.
Blanco P, Freedman S, Lopez M, Ollero M, Comen E, Laposata M, Alvarez J: Oral docosahexaenoic acid given to pregnant mice increases the amount of surfactant in lung and amniotic fluid in preterm fetuses. Am J Obstet Gynecol 2004;190:1369-1374.
40.
Sharma D, Nkembi AS, Aubry E, Houeijeh A, Butruille L, Houfflin-Debarge V, Besson R, Deruelle P, Storme L: Maternal PUFA omega-3 supplementation prevents neonatal lung injuries induced by hyperoxia in newborn rats. Int J Mol Sci 2015;16:22081-22093.
41.
Harris WS, Baack ML: Beyond building better brains: bridging the docosahexaenoic acid (DHA) gap of prematurity. J Perinatol 2015;35:1-7.
42.
Singer P, Theilla M, Fisher H, Gibstein L, Grozovski E, Cohen J: Benefit of an enteral diet enriched with eicosapentaenoic acid and gamma-linolenic acid in ventilated patients with acute lung injury. Crit Care Med 2006;34:1033-1038.
43.
Pacht ER, DeMichele SJ, Nelson JL, Hart J, Wennberg AK, Gadek JE: Enteral nutrition with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants reduces alveolar inflammatory mediators and protein influx in patients with acute respiratory distress syndrome. Crit Care Med 2003;31:491-500.
44.
Zhang P, Lavoie PM, Lacaze-Masmonteil T, Rhainds M, Marc I: Omega-3 long-chain polyunsaturated fatty acids for extremely preterm infants: a systematic review. Pediatrics 2014;134:120-134.
45.
Politi L, Rotstein N, Carri N: Effects of docosahexaenoic acid on retinal development: cellular and molecular aspects. Lipids 2001;36:927-935.
46.
Connor KM, SanGiovanni JP, Lofqvist C, Aderman CM, Chen J, Higuchi A, Hong S, Pravda EA, Majchrzak S, Carper D, Hellstrom A, Kang JX, Chew EY, Salem N Jr, Serhan CN, Smith LE: Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 2007;13:868-873.
47.
Pawlik D, Lauterbach R, Turyk E: Fish-oil fat emulsion supplementation may reduce the risk of severe retinopathy in VLBW infants. Pediatrics 2011;127:223-228.
48.
Pawlik D, Lauterbach R, Walczak M, Hurkala J, Sherman MP: Fish-oil fat emulsion supplementation reduces the risk of retinopathy in very low birth weight infants: a prospective, randomized study. JPEN J Parenter Enteral Nutr 2014;38:711-716.
49.
Beken S, Dilli D, Fettah ND, Kabatas EU, Zenciroglu A, Okumus N: The influence of fish-oil lipid emulsions on retinopathy of prematurity in very low birth weight infants: a randomized controlled trial. Early Hum Dev 2014;90:27-31.
50.
D'Ascenzo R, Savini S, Biagetti C, Bellagamba MP, Marchionni P, Pompilio A, Cogo PE, Carnielli VP: Higher docosahexaenoic acid, lower arachidonic acid and reduced lipid tolerance with high doses of a lipid emulsion containing 15% fish oil: a randomized clinical trial. Clin Nutr 2014;33:1002-1009.
51.
Vlaardingerbroek H, Vermeulen MJ, Carnielli VP, Vaz FM, van den Akker CH, van Goudoever JB: Growth and fatty acid profiles of VLBW infants receiving a multicomponent lipid emulsion from birth. J Pediatr Gastroenterol Nutr 2014;58:417-427.
52.
Hadley KB, Ryan AS, Forsyth S, Gautier S, Salem N: The essentiality of arachidonic acid in infant development. Nutrients 2016;8: pii:E216.
53.
Suganuma H, Arai Y, Kitamura Y, Hayashi M, Okumura A, Shimizu T: Maternal docosahexaenoic acid-enriched diet prevents neonatal brain injury. Neuropathology 2010;30:597-605.
54.
Vincent JL, Opal SM, Marshall JC, Tracey KJ: Sepsis definitions: time for change. Lancet 2013;381:774-775.
55.
Aghai ZH, Saslow JG, Meniru C, Porter C, Eydelman R, Bhat V, Stahl G, Sannoh S, Pyon K, Hewitt C, Bhandari V: High-mobility group box-1 protein in tracheal aspirates from premature infants: relationship with bronchopulmonary dysplasia and steroid therapy. J Perinatol 2010;30:610-615.
56.
Zamora R, Grishin A, Wong C, Boyle P, Wang J, Hackam D, Upperman JS, Tracey KJ, Ford HR: High-mobility group box 1 protein is an inflammatory mediator in necrotizing enterocolitis: protective effect of the macrophage deactivator semapimod. Am J Physiol Gastrointest Liver Physiol 2005;289:G643-G652.
57.
Lin PW, Stoll BJ: Necrotising enterocolitis. Lancet 2006;368:1271-1283.
58.
Caplan MS, Russell T, Xiao Y, Amer M, Kaup S, Jilling T: Effect of polyunsaturated fatty acid (PUFA) supplementation on intestinal inflammation and necrotizing enterocolitis (NEC) in a neonatal rat model. Pediatr Res 2001;49:647-652.
59.
Ohtsuka Y, Okada K, Yamakawa Y, Ikuse T, Baba Y, Inage E, Fujii T, Izumi H, Oshida K, Nagata S, Yamashiro Y, Shimizu T: Omega-3 fatty acids attenuate mucosal inflammation in premature rat pups. J Pediatr Surg 2011;46:489-495.
60.
Lu J, Jilling T, Li D, Caplan MS: Polyunsaturated fatty acid supplementation alters proinflammatory gene expression and reduces the incidence of necrotizing enterocolitis in a neonatal rat model. Pediatr Res 2007;61:427-432.
61.
De Plaen IG, Liu SX, Tian R, Neequaye I, May MJ, Han XB, Hsueh W, Jilling T, Lu J, Caplan MS: Inhibition of nuclear factor-κB ameliorates bowel injury and prolongs survival in a neonatal rat model of necrotizing enterocolitis. Pediatr Res 2007;61:716-721.
62.
Carlson SE, Montalto MB, Ponder DL, Werkman SH, Korones SB: Lower incidence of necrotizing enterocolitis in infants fed a preterm formula with egg phospholipids. Pediatr Res 1998;44:491-498.
63.
Fewtrell MS, Morley R, Abbott RA, Singhal A, Isaacs EB, Stephenson T, MacFadyen U, Lucas A: Double-blind, randomized trial of long-chain polyunsaturated fatty acid supplementation in formula fed to preterm infants. Pediatrics 2002;110:73-82.
64.
Clandinin MT, Van Aerde JE, Merkel KL, Harris CL, Springer MA, Hansen JW, Diersen-Schade DA: Growth and development of preterm infants fed infant formulas containing docosahexaenoic acid and arachidonic acid. J Pediatr 2005;146:461-468.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.